Business Wire

MODULEX

5.5.2022 15:02:06 CEST | Business Wire | Pressemeddelelse

Del
Modulex A/S med hovedkontor i Billund afsluttede 2021 med et økonomisk godt resultat på trods af endnu et udfordrende pandemiår.

Modulex A/S er globalt markedsledende inden for visuel kommunikation med 30 salgsenheder og flere produktionsfaciliteter rundt omkring i verden. Modulex A/S leverer wayfinding og arkitektoniske skilteløsninger samt multi-site brandimplementering og er den førende producent af systemskilte på verdensplan.

Koncernen sluttede 2021 med et EBITDA resultat på 17 mio. kr.

Mens koncernen som helhed leverede et flot resultat, er flere salgsenheder som fx Modulex Hospitality, der primært leverer skilteløsninger til internationale hotelkæder og ferieresorts, fortsat alvorligt påvirket af den globale pandemi og er først begyndt at se tegn på opsving i år. På trods af at det mange steder stadig er vanskeligt fysisk at besøge projekter og kunder, holdt de lokale kontorer verden over fast. Globalt set har Modulex Gruppen haft det bedste år i koncernens historie og har i løbet af året leveret og implementeret nogle meget store virksomhedsrebrands i både USA og Vesteuropa.

”Set i lyset af det pres, vi oplever på leveringstider og råmaterialer som aluminium, er vores resultat meget flot," siger Ketil M. Staalesen, administrerende direktør og hovedaktionær i Modulex Gruppen. "Vores produktionsteam udnyttede partnerskaber etableret gennem mange års samarbejde til at sikre, at vi kunne imødekomme vores kunders krav. Vores forretningsudviklingsstrategi fokuserede på at fremme miljøvenlige produkter som Etronit og Greenbond™, som er mindre påvirket af leveringsmæssige udfordringer."

Modulex Gruppen vil i 2022 fokusere på design-build-strategien, globale kunder, mere miljøvenlige produkter og lanceringen af ​​den cloud-baserede projektstyringssoftware e-Modulex. Modulex har allerede indgået nye.

"2022 bliver stadig en udfordring," siger Staalesen. “Men vores solide forretningsstrategi og vores ledelsesteams evne til at kæmpe gennem de seneste to år inspirerer mig. Jeg kunne ikke være mere stolt af dem, og jeg forventer, at vi overgår vores forventninger i år."

www.modulex.com

Om Modulex Gruppen:

Modulex Gruppen, som blev grundlagt i 1963 af LEGO-koncernen og som siden 2009 har været ejet af ledelsen samt andre eksterne investorer, er global markedsleder inden for visuel kommunikation og brandimplementering. Med rod i dansk designekscellence og et modulært skiltekoncept har Modulex udviklet sin platform yderligere med design, wayfinding, brugerdefinerede løsninger og brandimplementeringer. Fabrikken i Billund, som er ISO 9001-certificeret, lancerede i 2019 en mere miljøvenlig produktlinje. Modulex Billund blev tildelt Green Network-diplomet for niende år i træk. Modulex Gruppen har fem fabrikker globalt. Koncernen er repræsenteret i over 300 byer på tværs af 45 lande, hvilket giver Modulex Gruppen den nødvendige rækkevidde og evne til at leve op til sit løfte om global vision, lokal rækkevidde og én virksomhed.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye